GlassScriptPhysician profile
Prameela D Baddigam
NPI 1952302861
$8,112.43
in general payments reported to CMS, 2019-2025
28 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $321 · 2021: $1,509 · 2022: $1,438 · 2023: $1,393 · 2024: $966 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,194.34 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $763.77 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $590.82 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $588.92 | 2019-2022 | |
| Corium, LLC | $541.81 | 2022-2025 | Azstarys |
| Abbvie INC. | $532.42 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $396.37 | 2021-2022 | |
| Alkermes, INC. | $396.24 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $336.40 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $319.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.11 | 2019-2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $256.29 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $253.62 | 2019-2023 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $234.14 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $224.94 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $203.63 | 2020-2025 | Fanapt |
| Indivior INC. | $195.67 | 2022-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $155.86 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $150.87 | 2021-2023 | Qelbree |
| Braeburn INC. | $125.59 | 2023-2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $71.78 | 2025 | Jornay Pm |
| Allergan, INC. | $65.93 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $63.48 | 2023-2024 | Quviviq |
| Bioxcel Therapeutics, INC. | $56.08 | 2023 | Igalmi |
| Orexo US, INC. | $54.75 | 2023-2025 | Zubsolv |
| Bausch Health US, LLC | $49.80 | 2019-2022 | |
| Validus Pharmaceuticals LLC | $13.40 | 2023 | Equetro |
| Brainsway USA INC | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prameela Baddigam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.